Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Muscle-invasive Urothelial Carcinoma”

201 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 201 results

Testing effectiveness (Phase 2)Looking for participantsNCT07322263
What this trial is testing

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Who this might be right for
Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more
Michael A. O'Donnell 174
Not applicableStudy completedNCT06818799
What this trial is testing

Thulium Laser En-bloc Resection of Primary Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Transitional Cell Carcinoma
Helwan University 50
Not applicableEnded earlyNCT02202044
What this trial is testing

Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection

Who this might be right for
Bladder Carcinoma
University of Colorado, Denver 13
Very early researchActive Not RecruitingNCT04018053
What this trial is testing

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

Who this might be right for
Bladder CancerUrothelial Carcinoma
Brigham and Women's Hospital 16
Large-scale testing (Phase 3)Looking for participantsNCT07067749
What this trial is testing

Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerBladder Cancer Requiring CystectomyBladder Carcinoma+2 more
University of Rome Tor Vergata 92
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07142200
What this trial is testing

A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer
RenJi Hospital 45
Large-scale testing (Phase 3)Active Not RecruitingNCT03091660
What this trial is testing

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Who this might be right for
Stage 0 Bladder Urothelial CarcinomaStage 0is Bladder Urothelial CarcinomaStage I Bladder Urothelial Carcinoma
SWOG Cancer Research Network 1,000
Testing effectiveness (Phase 2)Study completedNCT03617913
What this trial is testing

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Who this might be right for
Bladder Carcinoma Infiltrating the Muscle of the Bladder WallStage II Bladder Cancer AJCC v8Stage II Renal Pelvis Cancer AJCC v8+9 more
Mayo Clinic 2
Large-scale testing (Phase 3)Not Yet RecruitingNCT07207824
What this trial is testing

DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNMIBC
Fudan University 182
Testing effectiveness (Phase 2)UnknownNCT05495724
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 176
Testing effectiveness (Phase 2)Looking for participantsNCT06571708
What this trial is testing

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

Who this might be right for
Bladder CancerMuscle-Invasive Bladder Carcinoma
Columbia University 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT04386746
What this trial is testing

Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

Who this might be right for
Urothelial Carcinoma BladderBladder Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 27
Large-scale testing (Phase 3)WithdrawnNCT07313891
What this trial is testing

Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Bladder (Urothelial, Transitional Cell) CancerUrothelial Carcinoma Bladder+1 more
Relmada Therapeutics, Inc.
Testing effectiveness (Phase 2)Study completedNCT02015104
What this trial is testing

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Who this might be right for
Bladder Cancer
National Cancer Institute (NCI) 32
Large-scale testing (Phase 3)Not Yet RecruitingNCT07480356
What this trial is testing

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNon-Muscle Invasive Bladder CarcinomaNon-muscle Invasive Bladder Cancer With Carcinoma in Situ
Protara Therapeutics 284
Large-scale testing (Phase 3)Ended earlyNCT02450331
What this trial is testing

Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

Who this might be right for
Carcinoma, Transitional Cell
Hoffmann-La Roche 809
Testing effectiveness (Phase 2)Active Not RecruitingNCT02845323
What this trial is testing

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Who this might be right for
Urothelial CarcinomaBladder Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 15
Large-scale testing (Phase 3)Study completedNCT05136898
What this trial is testing

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
UroGen Pharma Ltd. 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT03609216
What this trial is testing

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Who this might be right for
Infiltrating Bladder Urothelial CarcinomaStage II Bladder Urothelial CarcinomaStage III Bladder Urothelial Carcinoma
Alliance for Clinical Trials in Oncology 237
Early research (Phase 1)WithdrawnNCT05259397
What this trial is testing

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Bladder Cancer
Pfizer
Load More Results